Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul 2;5(1):114.
doi: 10.1038/s41392-020-00225-4.

Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment

Yifan Zhang  1   2 , Qun-Ying Lei  3   4   5
Affiliations
Comment

Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment

Yifan Zhang et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Pancreatic cancer microenvironment has long been known to be immunosuppressive, however, the immune responses to neoantigen expression remain elusive. Hedge et al. engineered a neoantigen-expressing PDAC mouse model and revealed the cDC-scarce TH17-abundant immune milieu. Boosting cDCs infiltration using Flt3L and CD40 agonist could significantly increase intratumoral CD8+ and TH1 cell number and extend survival in combination with radiation therapy
See this image and copyright information in PMC

Comment on

References

    1. Hegde S, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020;37:289–307.e289. doi: 10.1016/j.ccell.2020.02.008. - DOI - PMC - PubMed
    1. Neoptolemos JP, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 2018;15:333–348. doi: 10.1038/s41575-018-0005-x. - DOI - PubMed
    1. Dougan M, Dranoff G, Dougan SK. Cancer immunotherapy: beyond checkpoint blockade. Annu. Rev. Cancer Biol. 2019;3:55–75. doi: 10.1146/annurev-cancerbio-030518-055552. - DOI - PMC - PubMed
    1. Evans RA, et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight. 2016;1:e88328. doi: 10.1172/jci.insight.88328. - DOI - PMC - PubMed
    1. Balachandran VP, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551:512–516. doi: 10.1038/nature24462. - DOI - PMC - PubMed

Publication types